A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Trial details
- Registry ID
- NCT07428616
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as XL092
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaNCT07428616 | Exelixis | Phase 2 | Recruiting | 2028-02-29Estimated |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574 | Exelixis | Phase 3 | Enrolling by invitation | 2030-05-31Estimated |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsNCT06943755 | Exelixis | Phase 2, Phase 3 | Recruiting | 2029-06-30Estimated |
| Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06082167 | Exelixis | Phase 2, Phase 3 | Active not recruiting | 2028-08Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |